Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

Written by Customer Service on March 5, 2021. Posted in Public Companies.

First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19T-Detect COVID correctly confirmed recent or prior COVID-19 infections 97.1% of the time from date of RT-PCR diagnosis with 100% specificitySEATTLE, March 05, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for T-Detect™ COVID to confirm recent or prior COVID-19 infection. This first-in-class T cell- based test is the first indication resulting from Adaptive’s TCR-Antigen Map collaboration with...

ION announces Rights Offering for new convertible Second Lien Notes or common stock

Written by Customer Service on March 5, 2021. Posted in Public Companies.

HOUSTON, March 05, 2021 (GLOBE NEWSWIRE) — ION Geophysical Corporation (NYSE: IO) announced today that it is proceeding with steps to launch its previously announced rights offering (“Rights Offering”) for its New Second Lien Convertible Notes (“New Notes”) or its Common Stock, as part of its restructuring transactions (the “Restructuring Transactions”) approved by shareholders on February 23, 2021. The Company has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”). The Company expects to launch the rights offering after the Registration Statement is declared effective by the SEC.Each of our shareholders as of March 15, 2021 (the “Record Date”) will receive one non-transferable subscription right (“Right”) for each share of our Common Stock they own. Each Right will entitle a holder to...

CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil

Written by Customer Service on March 5, 2021. Posted in Public Companies.

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman and Chief Medical Officer, Mahboob Rahman, M.D., Ph.D., Chief Scientific Officer and Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, will host an investment community webcast on Monday, March 8, 2021.Management will discuss the data from the recently completed Phase 3 trial for severe-to-critically ill COVID-19 patients, the regulatory path forward with several countries, as well as updates on other clinical...

DMG Announces Closing of Cdn$70 Million Private Placement Offering with Institutional Investors

Written by Customer Service on March 5, 2021. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) — DMG Blockchain Solutions Inc. (TSX-V: DMGI) (DMGGF:OTCQB US) (FRANKFURT:6AX) (“DMG” or the “Company”), a vertically integrated blockchain and cryptocurrency technology company, is pleased to announce that it has closed its previously announced sale to U.S. and foreign institutional investors of its common shares (“Common Shares“) and warrants to purchase common shares (“Warrants“) for aggregate gross proceeds to the Company of approximately Cdn$70 million (the “Private Placement“). Pursuant to the Private Placement, the Company issued 23,333,334 Common Shares and Warrants to purchase up to 11,666,667 Common Shares at a purchase price of...

CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab

Written by Customer Service on March 5, 2021. Posted in Public Companies.

VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported today the Phase 3 trial of leronlimab for the treatment of severe-to-critical patients with COVID-19 demonstrated continued safety, substantial improvement in the survival rate, and faster hospital discharge in critically ill COVID-19 patients. The trial’s data has been reported to the U.S. Food and Drug Administration (“FDA”), the U.K.’s Medicines & Healthcare product Regulatory Agency (“MHRA”) and Health Canada (“HC”), and the Company is in discussions with each to determine the best path forward for approval of leronlimab for treatment of COVID-19...

Canacol Energy Ltd. To Announce Fourth Quarter and Fiscal Year 2020 Financial Results on Thursday, March 18, 2021; Hold Conference Call on Friday, March 19, 2021

Written by Customer Service on March 5, 2021. Posted in Public Companies.

CALGARY, Alberta, March 05, 2021 (GLOBE NEWSWIRE) — Canacol Energy Ltd. (“Canacol” or the “Corporation”) (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its fourth quarter and fiscal year 2020 financial results on Thursday, March 18, 2021, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, March 19, 2021 at 8:00 a.m. MST / 10:00 a.m. ET.The conference call may be accessed by dial in or via webcast:All remarks made during the conference call will be current at the time of the call and may not be updated to reflect subsequent material developments.Fourth quarter and fiscal year 2020 financial results will be available through the Investor Relations section of the company’s website. A replay of the webcast will be available on our website until March 26, 2021....

Acreage Announces Annual Shareholder Meeting Date and Record Date

Written by Customer Service on March 5, 2021. Posted in Public Companies.

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRDF, ACRHF) today announced the date and record date for its 2021 annual general meeting of shareholders.On May 27th at 12:00 pm EDT, Acreage will host its annual general meeting of shareholders in a virtual meeting where Acreage management will announce the results of the shareholder votes on issues that will be announced prior to the meeting. The record date for the annual general meeting of shareholders will be April 1st. Annual meeting materials will be made available in Acreage’s public filings on both SEDAR (www.sedar.com) and with the U.S. Securities and Exchange Commission on the EDGAR website at www.sec.gov. The virtual conference can be accessed via Acreage’s investor relations website at...

Helios Fairfax Partners Corporation: Financial Results for the Year Ended December 31, 2020

Written by Customer Service on March 5, 2021. Posted in Public Companies.

TORONTO, March 05, 2021 (GLOBE NEWSWIRE) —NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are prepared using the recognition and measurement requirements of International Financial Reporting Standards, except as otherwise noted, and are unaudited.)Helios Fairfax Partners Corporation (TSX: HFPC.U) (formerly Fairfax Africa Holdings Corporation (“Fairfax Africa”)) announces fiscal year 2020 net loss of $206.6 million ($3.31 net loss per diluted share), compared to fiscal year 2019 net loss of $61.2 million ($1.01 net loss per diluted share), reflecting increased net realized losses on investments, transaction expenses and net foreign exchange losses in 2020.On...

Rockridge Resources Completes Oversubscribed Non-Brokered Financing

Written by Customer Service on March 5, 2021. Posted in Public Companies.

VANCOUVER, British Columbia, March 05, 2021 (GLOBE NEWSWIRE) — Rockridge Resources Ltd. (TSX-V: ROCK) (“Rockridge” or the “Company”) is pleased to announce that it has completed a non-brokered private placement financing for total gross proceeds of $2,511,300 (the “Private Placement”). The Company has issued 15,620,000 non flow-through units (the “Units”) at a price of CAD $0.125 per Unit and 3,991,429 flow-through units (the “FT Units”) at a price of CAD $0.14 per FT Unit.Each Unit is comprised of one common share and one warrant, each warrant entitling the holder to purchase one additional common share for a period of sixty months at a price of CAD $0.22 per share. Each FT Unit is comprised of one common share and one-half of one warrant, each whole warrant entitling the holder to purchase one non-flow through common...

Aya Gold & Silver Announces Approval to Acquire Algold Resources

Written by Customer Service on March 5, 2021. Posted in Public Companies.

Mont-Royal, March 05, 2021 (GLOBE NEWSWIRE) — Montreal, Quebec, March 5, 2021 – Aya Gold & Silver Inc. (TSX: AYA) (“Aya” or the “Corporation”) is pleased to announce that the Proposal made by Algold Resources Ltd. (“Algold”) to its creditors was approved today pursuant to which Aya will fund Algold’s Proposal and at closing, will become the sole shareholder of Algold (the “Transaction”). Under the terms of the Investment Agreement, Aya will provide Algold with C$100,000 in cash and distribute C$2,400,000 in Aya shares to Algold current shareholders to fund Algold’s Proposal.The Transaction is expected to close on or around April 30, 2021.Further details regarding the Proposal can be found on the Trustee’s website athttps://www.raymondchabot.com/fr/entreprises/dossiers-publics/algold-resources-ltd/ About Aya Gold &...

Day: March 5, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice